What Investors Actually Want to See

Capital access remains the most consequential operational challenge in cannabis — and the gap between operators who understand what investors need and those who don’t has never been wider. Federal Schedule I status, Section 280E tax exposure, SAFE Banking’s ongoing legislative uncertainty, and compression in multi-state operator (MSO) valuations have fundamentally changed the fundraising calculus. Whether you’re capitalizing a new license or pursuing a Series B to fund market expansion, investors are underwriting your fundamentals, your team, and your ability to perform under pressure.

Raising Capital for a Cannabis Startup

Friends-and-family rounds and angel checks still fund plenty of early-stage cannabis ventures, but the sophisticated capital has migrated toward specialized cannabis-focused funds — groups like Poseidon Investment Management, Merida Capital Partners, and Casa Verde Capital — along with family offices that have developed internal cannabis investment theses. Institutional banks remain largely sidelined, making private equity the default mechanism for funding licensing costs, facility buildouts, and pre-revenue operating burn.

What That Capital Actually Costs

Expect early-stage cannabis equity to price at significant dilution — 20% to 35% is not uncommon for seed rounds in competitive license markets. In states like New Jersey or New York where social equity licensing created new entrants with limited operating capital, investors have structured deals with aggressive liquidation preferences and anti-dilution provisions that founders often underestimate until a down round.

The Business Plan Investors Will Actually Read

Sophisticated cannabis investors want to see your cost-per-gram at harvest, your expected yield per square foot of canopy, your 280E tax modeling, and how your cash position holds up across three scenarios — base, downside, and stress. A cultivation startup in Michigan, for example, needs to model against a wholesale flower market where per-pound prices have fallen from over $2,000 in 2020 to under $400 in mature markets. Investors who have been burned by optimistic Michigan or Colorado projections will pressure-test your assumptions hard.

Team Composition Is Diligence, Not Just Optics

A CFO who has navigated 280E audits, a compliance officer with state regulatory board relationships, and a head of cultivation with documented yield consistency across multiple harvests carry real underwriting weight. When Schwazze (formerly Medicine Man Technologies) built out its Colorado and New Mexico footprint, the operational pedigree of its leadership team was a central part of its investor story. Investors aren’t just buying your license — they’re buying your team’s ability to execute under regulatory and market pressure.

Scalability Has a Specific Meaning in Cannabis

It means your SOPs can be replicated across facilities without quality degradation, your compliance workflows aren’t dependent on one person’s institutional knowledge, and your technology stack — particularly your seed-to-sale and ERP integration — can scale without a full rebuild. Startups that come to the table with Metrc already integrated into their operational reporting, automated batch tracking, and documented QC protocols signal to investors that growth won’t require reinventing the back office.

Qualifying for Growth Capital

For operating companies, the fundraising conversation is entirely different. You’re no longer selling a vision — you’re defending your numbers and demonstrating that additional capital will generate a return that justifies the risk premium investors must accept in this regulatory environment

The Financial Metrics That Actually Move the Needle

Growth-stage cannabis investors focus on segment-level metrics, not blended figures. A vertically integrated operator needs to show cultivation, manufacturing, and retail margins separately:

• Gross margin at the segment level: Industry benchmarks put healthy retail gross margins at 45–55% and cultivation at 50–60% before overhead allocation. If your numbers fall below those thresholds, be prepared to explain why and show a path to improvement.
• Inventory turn rate: Excess inventory is a silent margin killer in cannabis, particularly in flower where product aging accelerates discounting. A well-run dispensary group should be turning retail inventory every 20–30 days. Investors will pull this number directly from your seed-to-sale system.
• Cash flow from operations, not EBITDA: Because of 280E, cannabis EBITDA is a deeply flawed metric. A company can show positive EBITDA and still be cash-flow negative after paying its effective federal tax rate of 50–70% on gross profit. Growth capital investors increasingly want to see operating cash flow and free cash flow after tax.
• Revenue per square foot / revenue per door: These are the comparable metrics investors use to benchmark cultivators and dispensary groups against peers.

Your ERP Is Investor Infrastructure

Operators running integrated platforms — where Metrc compliance data, cultivation batch records, manufacturing logs, and financial reporting flow into a single system — can produce the kind of audit-ready, real-time operational reporting that dramatically shortens investor due diligence cycles. When a potential investor asks for trailing twelve months of inventory variance reports or cost-of-goods by SKU, the operators who can produce that in 48 hours versus six weeks are not the same investment risk. Platforms like Acumatica with cannabis-specific ERP extensions give operators the financial reporting infrastructure that institutional investors expect.

Compliance Track Record Is Underwritten Like Credit History

A single major violation — a Metrc discrepancy, a failed state inspection, an unreported employee — can kill a deal or reprice it significantly. Growth capital investors will review your state inspection history, your internal audit records, and your corrective action documentation. Companies that have built compliance into their operational DNA, rather than treating it as a checkbox exercise, present materially lower risk profiles. An operator like Cresco Labs or Green Thumb Industries didn’t become institutional-grade investments by accident — their compliance infrastructure was built to withstand scrutiny at scale.

Capital Deployment Clarity Is Non-Negotiable

If you’re raising $8 million to open three additional dispensary locations in Ohio, your investor presentation should include a site-level pro forma for each location, a build-out budget with contingency, a ramp-to-profitability timeline, and a sensitivity analysis showing what happens if average transaction value comes in 15% below projection. Vague statements about “market expansion” will not survive a serious due diligence process. Investors have been burned by cannabis operators who raised growth rounds and then struggled with execution — they now demand milestone-based tranches, board seats, and financial covenants that give them intervention rights if performance deviates from plan.

The Bottom Line

Capital is available in cannabis — but it has migrated decisively toward operators who have earned it through demonstrated performance. The days of raising on the promise of legalization tailwinds are over. Today’s cannabis investors are underwriting operational discipline, compliance integrity, financial transparency, and management credibility. If your financials can’t withstand scrutiny, your compliance history has gaps, or your team lacks the depth to scale, the capital conversation will be short.

The operators who are closing rounds in today’s market have built their businesses to be investor-ready from day one — not because they anticipated fundraising, but because running a tight operation and running a fundable operation are, in cannabis, exactly the same thing.